trastuzumab deruxtecan,trastuzumab
daiichi sankyo,astrazeneca
['trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'tdxd']
 think we need better her2 tests. ihc was designed for trastuzumab benefit. there s probably degree of tdxd benefit based on her2 levels.
Oncologist and tennis player